Applications, hearings, determinations, etc.: Lipomed, Inc.,

[Federal Register: September 10, 2001 (Volume 66, Number 175)]

[Notices]

[Page 47039-47040]

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

[DOCID:fr10se01-67]

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances; Application

Pursuant to section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Sec. 1301.34 of Title 21, Code of Federal Regulations(CFR), notice is hereby given that on April 19, 2001, Lipomed, Inc., One Broadway, Cambridge, Massachusetts 02142, made application by renewal to the Drug Enforcement Administration to be registered as an importer of the basic classes of controlled substances listed below:

Drug

Schedule

Cathinone (1235)........................... I Methaqualone (2565)........................ I Lysergic acid diethylamide (7315).......... I Marihuana (7360)........................... I Tetrahydrocannabinols (7370)............... I Mescaline (7381)........................... I 3,4,5-Trimethoxyamphetamine (7390)......... I 4-Bromo-2,5-dimethoxyamphetamine (7391).... I 4-Methyl-2,5-dimethoxyamphetamine (7395)... I 2,5-Dimethoxyamphetamine (7396)............ I 2,5-Dimethoxy-4-ethylamphetamine (7399).... I 3,4-Methylenedioxyamphetamine (7400)....... I 3,4-Methylenedioxy-N-ethylamphetamine

I (7404). 3,4-Methylenedioxymeth-

I amphetamine (7405)....................... Psilocybin (7437).......................... I Psilocyn (7438)............................ I Acetyldihydrocodeine (9051)................ I Dihydromorphine (9145)..................... I Heroin (9200).............................. I Tilidine (9750)............................ I Amphetamine (1100)......................... II Methamphetamine (1105)..................... II Amobarbital (2125)......................... II Secobarbital (2315)........................ II Phencyclidine (7471)....................... II Cocaine (9041)............................. II Codeine (9050)............................. II Dihydrocodeine (9120)...................... II Oxocodone (9143)........................... II Hydromorphone (9150)....................... II Benzoylecgonine (9180)..................... II Hydrocodone (9193)......................... II Levorphanol (9220)......................... II Methadone (9250)........................... II Dextropropoxyphene, bulk (non-dosage forms) II (9273). Morphine (9300)............................ II Thebaine (9333)............................ II Oxymorphone (9652)......................... II Alfentanil (9737).......................... II Fentanyl (9801)............................ II

The firm plans to import small reference standard quantities of finished commercial product from its sister company in Switzerland for sale to its customers for drug testing and pharmaceutical research and development.

Any manufacturer holding, or applying for, registration as a bulk manufacturer of these basic classes of controlled substances may file written comments on or objections to the application described above and may, at the same time, file a written request for hearing on such application in accordance with 21 CFR 1301.43 in such form as prescribed by 21 CFR 1316.47.

Any such comments, objections or requests for a hearing may be addressed, in quintuplicate, to the Deputy Assistant

[[Page 47040]]

Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filedno later than October 10, 2001.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice at 40 FR 43745-46 (September 23, 1975), all applicants for registration to import the basic classes of any controlled substances in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(a), (b), (c), (d), (e), and (f) are satisfied.

Dated: August 30, 2001. Laura M. Nagel, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 01-22567Filed9-7-01; 8:45 am]

BILLING CODE 4410-09-M